A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial

MLA

Shin Yoshida, et al. “A Phase I Study of Multi-HLA-Binding Peptides Derived from Heat Shock Protein 70/Glypican-3 and a Novel Combination Adjuvant of HLAG-3Ig and Poly-ICLC for Patients with Metastatic Gastrointestinal Cancers: YNP01 Trial.” Cancer Immunology, Immunotherapy, vol. 69, Mar. 2020, pp. 1651–62. EBSCOhost, https://doi.org/10.1007/s00262-020-02518-7.

APA

Shin Yoshida, Akira Saito, Nobuaki Suzuki, Yuki Nakagami, Hiroto Matsui, Koji Tamada, Michihisa Iida, Hiroaki Nagano, Masao Nakajima, Shigefumi Yoshino, Shigeru Takeda, Toshinari Uematsu, Hideki Arima, Yasunobu Kouki, Tomio Ueno, Satoshi Matsukuma, Shinobu Tomochika, Shigeru Yamamoto, Shun Doi, … Shinsuke Kanekiyo. (2020). A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial. Cancer Immunology, Immunotherapy, 69, 1651–1662. https://doi.org/10.1007/s00262-020-02518-7

Chicago

Shin Yoshida, Akira Saito, Nobuaki Suzuki, Yuki Nakagami, Hiroto Matsui, Koji Tamada, Michihisa Iida, et al. 2020. “A Phase I Study of Multi-HLA-Binding Peptides Derived from Heat Shock Protein 70/Glypican-3 and a Novel Combination Adjuvant of HLAG-3Ig and Poly-ICLC for Patients with Metastatic Gastrointestinal Cancers: YNP01 Trial.” Cancer Immunology, Immunotherapy 69 (March): 1651–62. doi:10.1007/s00262-020-02518-7.